当前位置： SCI文献检索 > Applied Health Economics and Health Policy期刊下所有文献 > Economic analysis of thrombo inCode, a clinical-genetic function for assessing the risk of venous thromboembolism.

Economic analysis of thrombo inCode, a clinical-genetic function for assessing the risk of venous thromboembolism.

Abstract：

BACKGROUND:Patients with venous thromboembolism (VTE) commonly have an underlying genetic predisposition. However, genetic tests nowadays in use have very low sensitivity for identifying subjects at risk of VTE. Thrombo inCode(®) is a new genetic tool that has demonstrated very good sensitivity, thanks to very good coverage of the genetic variants that modify the function of the coagulation pathway. OBJECTIVE:To conduct an economic analysis of risk assessment of VTE from the perspective of the Spanish National Health System with Thrombo inCode(®) (a clinical-genetic function for assessing the risk of VTE) versus the conventional/standard method used to date (factor V Leiden and prothrombin G20210A). METHODS:An economic model was created from the National Health System perspective, using a decision tree in patients aged 45 years with a life expectancy of 81 years. The predictive capacity of VTE, based on identification of thrombophilia using Thrombo inCode(®) and using the standard method, was obtained from two case-control studies conducted in two different populations (S. PAU and MARTHA; 1,451 patients in all). Although this is not always the case, patients who were identified as suffering from thrombophilia were subject to preventive treatment of VTE with warfarin, leading to a reduction in the number of VTE events and an increased risk of severe bleeding. The health state utilities (quality-adjusted life-years [QALYs]) and costs (in 2013 EUR values) were obtained from the literature and Spanish sources. RESULTS:On the basis of a price of EUR 180 for Thrombo inCode(®), this would be the dominant option (more effective and with lower costs than the standard method) in both populations. The Monte Carlo probabilistic analyses indicate that the dominance would occur in 100 % of the simulations in both populations. The threshold price of Thrombo inCode(®) needed to reach the incremental cost-effectiveness ratio (ICER) generally accepted in Spain (EUR 30,000 per QALY gained) would be between EUR 3,950 (in the MARTHA population) and EUR 11,993 (in the S. PAU population). CONCLUSION:According to the economic model, Thrombo inCode(®) is the dominant option in assessing the risk of VTE, compared with the standard method currently used.

journal_name

Appl Health Econ Health Policy

journal_title

Applied health economics and health policy

authors

Rubio-Terrés C,Soria JM,Morange PE,Souto JC,Suchon P,Mateo J,Saut N,Rubio-Rodríguez D,Sala J,Gracia A,Pich S,Salas E

doi

10.1007/s40258-015-0153-x

subject

Has Abstract

pub_date

2015-04-01 00:00:00

pages

233-42

issue

eissn

1175-5652

issn

1179-1896

journal_volume

pub_type

杂志文章

在线工具

Economic analysis of thrombo inCode, a clinical-genetic function for assessing the risk of venous thromboembolism.